c-erbB-2 Positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease
- 1 February 2001
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 37 (3) , 347-354
- https://doi.org/10.1016/s0959-8049(00)00395-6
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast CancerJNCI Journal of the National Cancer Institute, 1998
- Independent Prognostic Factors in Breast Cancer PatientsThe American Journal of Surgery, 1998
- Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein.Journal of Clinical Oncology, 1997
- Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.Journal of Clinical Oncology, 1995
- Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.Journal of Clinical Oncology, 1992
- HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.Journal of Clinical Oncology, 1992
- Association of C‐erbB‐2 protein over‐expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long‐term survival in breast cancerInternational Journal of Cancer, 1991
- The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancerBritish Journal of Cancer, 1991
- erb B-2 Is a Potent Oncogene When Overexpressed in NIH/3T3 CellsScience, 1987
- Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu OncogeneScience, 1985